Table 3.

4 Some common phamacological sighificant nuclear receptors

Receptor name Abbreviation Ligand Drugs Location Ligard blinding Mechanism of action
Type I
Androgen AR Testosterone All natural and symthetic Translocation to nucleus. Binding
glucocortticoids ( Ch.34) to HREs with to half-sites with an
Oestrogen ER𝛼, 𝛽 17𝛽 − 𝑜𝑒𝑠𝑡𝑟𝑎𝑑𝑖𝑜𝑙 mineralocorticoids(Ch. 30) inverted sequence. Rercuitment
Glucocorticoid GR𝛼 Cortisol, And sex steroids (Ch. 36) Cytosolic Homodimers of co-activators, transcription
corticosterone factors and other proteins.
Progesterone PR Progesterone Together with their
Mineralocorticoid MR Aldosterone Antagonists (e.g.raloxifene,
4-hydroxy-tamoxifen and
Mifepistone)
Type II
Retinoid X RXR 𝛼, 𝛽, 𝛾 9-cis-retinoic acid Retionds drugs (Ch. 28) Binding to HREs with to half-sites
Retinoic Acid RAR 𝛼, 𝛽, 𝛾 Vitamin A with an inverted or simple
Thyroid hormone TR 𝛼, 𝛽 T3, T4 Thyroid hormone drugs repeat sequence. Complexed with
(Ch.35) co-repessors, which are displaced
Peroxisome proliferator PPAR 𝛼, 𝛽, 𝛾, 𝛿 Fatty acids, Rosiglitazone, pioglitazone Nuclear Heterodimers following ligand binding,
prostaglandins (Ch. 32) often with PXR allowing the binding of
Constitutive CAR Androstane Stimulation of CYP co-activations
androstane synthesis and alteration of
Pregnane X PXR Xenobiotics drug metebolism (Ch. 10)
Only examples from classes I and II are included